share_log

Climb Bio Completes Transition To Immune-mediated Disease Focused Company; Expects Cash Runway Through 2027 To Enable Delivery Of Key Value Inflection Points

Benzinga ·  Oct 15 22:44
Climb Bio Completes Transition To Immune-mediated Disease Focused Company; Expects Cash Runway Through 2027 To Enable Delivery Of Key Value Inflection Points
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment